Delaware Hospice, Inc Southern Division Medicare Approved Location: 100 Patriots Way, Milford, Delaware 19963 Phone: (302) 856-7717 |
News Archive
Eisai Europe Ltd. today announced that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for approval of eribulin mesylate, also known as 'E7389', for the treatment of locally advanced or metastatic breast cancer in Europe. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai. Regulatory applications for eribulin mesylate have also been submitted in the United States and Japan.
The American Psychological Association condemned the administration's efforts to use federal rules to dismantle civil rights protections in health care for vulnerable populations, particularly transgender and gender non-conforming patients.
Utilizing Fluidigm Corporation's Dynamic Array™ and Digital Array™ integrated fluidic circuits (IFCs), Stanford University researchers to have discovered a much larger spectrum of differences between individual cells than has previously been demonstrated. Among these differences are the communication capabilities that emerge from the interactions of genetic circuitry that mediates cell-to-cell communication.
Tissue oxygenation is a measure of the oxygen level in biological tissue and is a useful clinical biomarker for tissue viability. Abnormal levels may indicate the presence of conditions such as sepsis, diabetes, viral infection, or pulmonary disease, and effective monitoring is important for surgical guidance as well as medical care.
Gene Security Network announced today that they have received a $2 million grant from the National Institutes of Health to conduct a clinical trial applying Parental Support technology for non-invasive prenatal diagnosis.
› Verified 9 days ago